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Abstract
Prion diseases have been observed to deregulate the transcription of erythroid genes, and prion protein knockout mice
have demonstrated a diminished response to experimental anemia. To investigate the role of the cellular prion protein
(PrP
C) in erythropoiesis, we studied the protein’s expression on mouse erythroid precursors in vivo and utilized an in vitro
model of the erythroid differentiation of murine erythroleukemia cells (MEL) to evaluate the effect of silencing PrP
C through
RNA interference. The expression of PrP
C and selected differentiation markers was analyzed by quantitative multicolor
flow cytometry, western blot analysis and quantitative RT-PCR. The silencing of PrP
C expression in MEL cells was achieved by
expression of shRNAmir from an integrated retroviral vector genome. The initial upregulation of PrP
C expression in
differentiating erythroid precursors was detected both in vivo and in vitro, suggesting PrP
C’s importance to the early stages
of differentiation. The upregulation was highest on early erythroblasts (1620063700 PrP
C / cell) and was followed by the
gradual decrease of PrP
C level with the precursor’s maturation reaching 4706230 PrP
C / cell on most mature CD71
2Ter119
+
small precursors. Interestingly, the downregulation of PrP
C protein with maturation of MEL cells was not accompanied by
the decrease of PrP mRNA. The stable expression of anti-Prnp shRNAmir in MEL cells led to the efficient (.80%) silencing of
PrP
C levels. Cell growth, viability, hemoglobin production and the transcription of selected differentiation markers were not
affected by the downregulation of PrP
C. In conclusion, the regulation of PrP
C expression in differentiating MEL cells mimics
the pattern detected on mouse erythroid precursors in vivo. Decrease of PrP
C protein expression during MEL cell maturation
is not regulated on transcriptional level. The efficient silencing of PrP
C levels, despite not affecting MEL cell differentiation,
enables created MEL lines to be used for studies of PrP
C cellular function.
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Introduction
The cellular prion protein (PrP
C) is expressed in cells of
various origins. It is conserved through the whole vertebrae class,
suggesting its importance in cellular physiology[1]. However, its
role in physiological processes remains enigmatic although PrP
C
plays a basic role in the pathogenesis of the fatal neurodegen-
erative disorders known as Transmissible Spongiform Enceph-
alopathies. Observation of PrP
C deficient mice (PrP
2/2) did not
reveal significant health problems. On the other hand,
experiments in cell cultures suggested that PrP
C is linked to
such processes as the prevention of apoptosis, copper metabolism
linked to oxidative stress, iron metabolism, signalization and
differentiation[2,3,4]. A connection between prion pathogenesis
and erythropoiesis was suggested by the downregulation of the a-
hemoglobin stabilizing protein (AHSP) mRNA during prion
disease[5]. A later study indicated that the disease progression
affected the transcription of several other murine erythroid
genes, e.g., Kell, GPA, band 3 and ankyrin[6]. A link between
PrP
C expression and erythropoiesis was also demonstrated in
PrP
2/2 mice after the experimental induction of hemolytic
anemia. Upon treatment with phenylhydrazine, PrP
2/2 mice
produced fewer reticulocytes than did PrP
+/+ mice. This result
was probably due to the reduced level of erythropoietin
production and higher percentage of apoptotic erythroid
precursors[7]. Apparently, the expression of PrP
C is generally
important in hematopoiesis. PrP
C is present on the surface of
mouse long-term hematopoietic stem cells (LT-HSCs) and
supports their self-renewal and engraftment during serial
transplantation. Quantitatively, 40% of mouse bone marrow
(BM) cells express PrP
C, and, from this population of cells, 80%
are erythroid cells[8]. CD34
+ human bone marrow stem cells
also express PrP
C[9,10], and circulating human and mouse red
blood cells have similarly low levels of PrP
C on their cellular
membranes[11,12]. A widely used model for the study of
erythroid differentiation in vitro is presented by murine
erythroleukemia (MEL) cells. MEL cells are blocked at the
proliferative proerythroblast stage, and, after the addition of
polar substances, e.g., hexamethylene bisacetamide (HMBA),
they lose their proliferative capacity and enter cell-cycle arrest.
This process is characterized by structural (decreased cell volume
and nuclear condensation) and biochemical changes (activation
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24599of erythroid genes, hemoglobin accumulation), which resemble
those exhibited by natural erythroid differentiation[13]. Gou-
goumas and colleagues demonstrated transcriptional activation
at the mRNA level of the PrP gene in growth-arrested MEL
cells[14]. Our study extends their observations by demonstrating
divergences in the regulation of PrP
C at the protein and mRNA
levels during inducer-mediated erythroid differentiation and cell-
growth arrest caused by confluency. In addition, we exploited
MEL cell lines with stably downregulated levels of PrP
C to study
its importance in the differentiation of MEL cells.
Results
Regulation of PrP
Cexpression on mouse bone marrow
and spleen erythroid precursors
Erythroid precursors were gated according their Ter119 and
CD71 signals and the forward scatter (FSC) signals to the proE,
EryA, EryB and EryC subpopulations (Fig. 1 A). CD71
+Ter119
+/2
bone marrow proerythroblasts (proE) expressed 780063100 PrP
C
molecules / cell, assuming that one molecule of mAb AH6 binds
one molecule of PrP
C. The expression of CD71
+Ter119
+ basophilic
erythroblasts (EryA) was elevated to 1620063700 PrP
C / cell and
decreased in late basophilic and polychromatic erythroblasts (EryB)
to 510061100 PrP
C / cell and was also diminished in late
CD71
2Ter119
+ small precursors (EryC) (4706230 PrP
C / cell).
Corresponding erythroid precursors in the spleen expressed
42006600, 1340065200, 460061400 and 6806280 PrP
C / cell,
respectively (Fig. 1 B).
Regulation of PrP
C expression during the erythroid
differentiation of MEL cells
MEL cells were grown for five days in the absence or presence of
5 mM HMBA. The cells increased their expression of Prnp mRNA,
reaching 1361.2 -fold and 8.762.8-fold relative expression after
120 hours in uninduced and differentiating cells, respectively (Fig. 2
A and B). While the level of PrP mRNA in the differentiating cells
more than doubled within 24 h after induction, a similar increase in
the uninduced cells was observed after 48 h in culture when cells
were reaching confluency. At the protein level, the uninduced cells
increased their PrP
C, reaching a maximum expression in confluent
culture at 96–120 h (Fig. 2C) which correlated with the expression
of Prnp mRNA. In contrast, the expression of the PrP
C protein in
differentiating cells peaked at 24–48 h post-induction (Fig. 2D) with
a subsequent decrease to almost its basal level at 120 h, as
demonstrated by densitometry (Fig. 2F). The increased density of
the PrP
C band on the WB was already visible within 6 h post-
induction (not shown).These results were confirmed by quantitative
FACS analysis, which demonstrated approximately twofold in-
crease of PrP
C membrane expression after 24 h of differentiation,
with a subsequent return to the basal level after 96 h (Fig. 2E).
Dexamethasone treatment of MEL cells lowers their
expression of PrP
C in confluent culture irrespective of
production of hemoglobin
Induction of MEL cell differentiation by incubation with
HMBA for 24 h with their subsequent incubation in the media
Figure 1. The expression of PrP
C on mouse bone marrow (BM) and spleen erythroid precursors is upregulated in early erythroblasts
and, then, decreases with the cells’ maturation. (A) Gating strategy for erythroid precursors: upper left - scattergram of BM cells; upper right –
gating of viable 7-AAD negative cells (BM live); lower left – live BM cells labeled with CD71-FITC (FL1) and Ter119-eFluor450 (FL5): ProE -
CD71
+Ter119
+/2 proerythroblasts; Ter119
+ cells were further gated on CD71-FITC (FL1) and FSC plot (lower right): EryA - large CD71
+ early basophilic
erythroblasts, EryB - small CD71
+ late basophilic and polychromatic erythroblasts, EryC - small CD71
- orthochromatic erythroblasts and reticulocytes.
(B) Quantitative FACS analysis of PrP
C expression on erythroid precursors in mouse bone marrow and spleen. Expression of PrP
C on early basophilic
erythroblasts (EryA) is significantly higher (p.0.005, n=5) in comparison with proerythroblasts (ProE), both in BM (upper) and spleen (lower). The
initial increase of expression is followed by its decrease on late basophilic and polychromatic erythroblasts (EryB), and most mature small precursors
(EryC) express a low number of PrP
C. Quantification is based on assumption that one IgG molecule of MAb AH6 binds to one molecule of PrP
C.
doi:10.1371/journal.pone.0024599.g001
Expression of Prion Protein in Erythroid Cells
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24599without HMBA (H/M), or the inclusion of 4 mM dexamethasone
in the medium with HMBA (HD/HD), both led to a comparable
(,60%) reduction of MEL cells hemoglobinization after 120 h of
culture (Fig. 3 A). The H/M treatment was connected with the
significant increase of PrP
C level (,220%) at 120 h comparable to
the increase recorded in non-differentiated confluent cells (NT)
(Fig. 3 B, C). At the other hand, HD/HD treatment led to low
PrP
C level (,80%), lower than in differentiated fully hemoglobi-
nized MEL cells (H/H). Treatment of MEL cells with up to
40 mM dexamethasone did not influence the initial up-regulation
of PrP
C in HMBA stimulated cells 24 h post induction, but
generally led to lower PrP
C levels in comparison with NT cells
after 120 h in culture (Fig. 3 B, C). Interestingly, induction of PrP
C
expression in growth-arrested confluent culture led to a different
PrP western blot pattern with predominant ,26 kDa band which
is much less present in both, fully differentiated or actively dividing
Figure 2. Initial increase of PrP
C protein expression in differentiating MEL cells is followed by its downregulation. (A) Transcriptional
activation of the Prnp gene in uninduced MEL cells (- HMBA) correlates with growth arrest in confluent culture at 72 h, as demonstrated by qRT-PCR.
A similar, but lower, increase of PrP mRNA is seen in cells induced to erythroid differentiation (+ HMBA) (B). Progress of cell differentiation is
monitored by overall hemoglobin level (full line, n=2, mean 6 SD). The amount of PrP
C protein on western blots (WB) in uninduced cells (C)
correlates with the level of mRNA (A). In contrast, the amount of PrP
C protein in differentiating cells (D) is highest 24–48 h after induction and, then, is
downregulated, as shown by densitometry (F), despite the level of PrP mRNA continues to rise (B). Blots were developed with a mix of PrP
C mAbs
(AH6, AG4, 6H4) and actin antibody was used as a loading control. Surface expression of PrP
C on HMBA induced differentiating MEL cells (number of
mAb AH6 IgG molecules / cell) measured by quantitative flow cytometry (E) correlates with the levels detected by WB (F) (n=2, means 6 range).
doi:10.1371/journal.pone.0024599.g002
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C
were not caused by differences in gel loading, as demonstrated by
actin labeling.
Retroviral vector delivery of anti-Prnp shRNAmir leads to
stable and efficient PrP
C silencing
Both spinfection and co-cultivation methods led to efficient
(,90%) silencing of PrP
C at the mRNA (Fig. 4 A) and protein
levels (Fig. 4 B) by LP1 and LP2 constructs in comparison with
control construct LN. The LP5 construct did not produce any
downregulation of PrP
C levels (Fig. 4 B). Retroviral infection of
cells did not induce cell-protective effects, as demonstrated by
qRT-PCR analysis of chosen interferon-stimulating genes Oas1a,
Rnase1 and Eif2ak2 (not shown). The silencing of PrP
C in LP1 and
LP2 lines was stable during the course of HMBA-induced cell
differentiation (Fig 5). In comparison with LN, LP1- and LP2-
transduced cells exhibited 79% and 84% inhibition of Prnp
mRNA expression at the beginning of differentiation and 93% and
96% after 120 h of differentiation, respectively (Fig. 5 A). The
levels of Prnp mRNA and protein during differentiation of the
control LN-transduced cells (Fig. 5 A, C) was upregulated similarly
as in non-manipulated MEL cells (Fig. 2 B, D). The stability of
PrP
C silencing was confirmed by quantitative FACS analysis,
which demonstrated downregulation of PrP
C at the cell membrane
ranging from 17% (LP1) and 12% (LP2) to 8% (LP1) and 5%
(LP2) of its expression (100%) in LN-transduced cells at the
beginning of differentiation and after 48 h, respectively (Fig. 5 B).
These results were confirmed by western blot analysis in which we
could faintly detect PrP
C in LP1 and LP2 cells only after 24 hours,
while the protein in LN-transduced cells was readily detected
(Fig. 5 C).
Silencing of the Prnp gene by RNAi does not affect
HMBA-induced differentiation of MEL cells
Cell numbers in differentiating LN and LP1 lines increased
similarly, reaching 2.4610
6 cells/mL at 72 h. The LP2-trans-
duced cell line produced slightly more cells, with a maximum of
3.0610
6 cells/mL at 72 h (Fig. 6 A). In a Trypan Blue exclusion
assay, all cell lines demonstrated a similar viability (,94%) over a
72-h post-induction period and, also, a similar slight decrease of
viability after 96 and 120 h (Fig. 6 B). We did not detect any
differences in the transcriptional levels of proapoptotic Bax (not
shown). The dynamic of hemoglobin production was comparable
in all cell lines, irrespective of the level of PrP
C (Fig. 6 C).
Similarly, surface expression of the transferrin receptor (CD71)
was similarly regulated in all cell lines (Fig. 6 D). Also, no
difference was demonstrated in the levels of c-myb mRNA, which
were downregulated approximately eightfold after 24 h post-
induction in all lines. After 48 h, c-myb mRNA was downregu-
lated to ,2% of the starting level and remained silenced until the
end of the experiment (not shown). Similarly, monitoring of the
erythroid markers Eraf and Hba (Fig. 7A and B) and GATA-1 (not
shown) during the differentiation of cells at the transcriptional level
indicated analogous expression in all lines, irrespective of PrP
C
levels.
Discussion
The role of PrP
C in cellular physiology has been proposed for a
variety of processes, but with no prevailing consensus to date[1].
The downregulation of erythroid genes during prion infection has
established a link between the peripheral pathogenesis of prion
diseases and erythropoiesis. However, it is not clear if the effect is
caused by direct interaction of prion particles with erythroid cells
or if it is triggered by some yet unknown humoral response to the
infection. The expression of PrP
C on circulating red blood cells
(RBCs) of closely related nonhuman primates varies from several
thousand per cell to zero[15], implying that its function on mature
erythrocytes is not conserved. Griffiths et al. demonstrated the
regulation of PrP
C expression during the differentiation of cultured
human erythroblasts in vitro, indicating that it may play a role in
the differentiation of erythroid precursors. PrP
C was found mostly
in the perinuclear region of proerythroblasts, and the amount of
PrP
C declined as erythroid cells matured[16]. Human and mouse
RBCs express approximately 200 PrP
C molecules per cell[11],
suggesting a similar regulation of its expression in the erythroid
lineage in both species. In this study, we demonstrated that the
surface expression of PrP
C on erythroid precursors in the mouse
bone marrow and spleen follows a similar pattern as the cells
mature. The protein’s levels first increase with basophilic
erythroblasts, expressing more than twice as much PrP
C as
proerythroblasts, and then declines significantly in late basophilic
and polychromatic erythroblasts, with most mature small ery-
throid precursors expressing only around 500 PrP
C molecules per
cell. This pattern of expression is suggestive of PrP
C’s involvement
in the early stages of erythroid differentiation. The differentiation
of MEL cells in culture is known to resemble the in vivo process,
with similar maturation stages: proerythroblast-like, erythroblasts-
like and, occasionally, reticulocyte-like[16,17]. The surface
expression of PrP
C on uninduced MEL cells in the exponential
phase of growth was approximately six times higher than that
observed on proerythroblasts in the mouse bone marrow or spleen.
However, the induction of differentiation led to nearly doubling of
the PrP
C number on MEL cell membranes within 24 h, which
resembled a similar increase of PrP
C expression on basophilic
erythroblasts in vivo. In agreement with previous observations in
vivo, we found that this initial upregulation was followed by a
gradual downregulation of PrP
C surface levels along with the
progression of MEL cells’ differentiation. This decrease did not
reach the degree observed in small CD71
-Ter119
+ erythroid
precursors in vivo, which is in line with the limited ability of
differentiating MEL cells to reach this stage of maturation. The
differentiation of MEL cells is composed of two separate events,
growth arrest and terminal differentiation. Both processes are
characterized by the activation of early (cell-cycle control) and late
(morphological changes) genes[17]. The first period lasts approx-
imately 12 hours, after which the first committed cells materialize.
The majority of cells are terminally differentiated between 24 and
50 h[18]. In agreement with previous studies by Gougomas
et al.[14], we found that the Prnp gene in MEL cells is
transcriptionally activated both during inducer-mediated differen-
tiation and in confluent cells undergoing cell-cycle arrest. In
addition, we were able to demonstrate the regulation of PrP
C at
the protein level by western blot. Interestingly and in accordance
with the flow cytometry results, in differentiating cells, the
expression of the protein was downregulated after an initial
increase, even though the level of PrP mRNA continued to rise.
This result suggests that MEL cells’ differentiation leads to a
translational regulation of PrP
C levels[19] not seen in uninduced
cells undergoing cell-cycle arrest. Alternatively, more differentiated
cells could degrade PrP
C at an increased rate, as has been
proposed to explain the disparity between PrP protein and mRNA
levels in different types of neuronal cells[20]. The downregulation
of PrP
C protein during the differentiation of highly responsive
subclones of MEL cells was recently reported by Otsuka et al.[21];
however, their study did not detect an initial increase of PrP
C
expression, most likely due to the different status of cells at the
point of induction. Stimulation of the glucocorticoid receptor by
Expression of Prion Protein in Erythroid Cells
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C expression after the induction of MEL cells’ differentiation by HMBA is not affected by
dexamethasone. (A) Hemoglobin levels 120 hrs post induction of MEL cells differentiation. Cells were treated with HMBA (H), Dexamethasone (D)
or the combination thereof (HD). After 24 hrs media were exchanged and the treatment continued, or was changed for different one as shown on x-
axis labels (M stands for DMEM medium only). Non-treated (NT) control represents cells kept in DMEM only. Cell lysates were normalized to the total
protein content (measured by BCA assay) and hemoglobin was quantified by TMB assay. (B) Western blot analysis of PrP
C expression. Samples were
harvested after 24 and 120 hrs treatments described above. NT control at 0 hrs represents the initial conditions of MEL culture before treatment. The
gel loading was normalized to the total protein content (measured by BCA assay) and controlled by actin staining. The blot is a representative of
three independent experiments. (C) Quantification of the PrP
C level on western blots by densitometry. Graph columns represent the average density
of PrP
C bands and error bars represent the standard deviations; PrP
C expression level of NT control at 0 hrs was set as 100% (*p,0.05, n=3).
doi:10.1371/journal.pone.0024599.g003
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erythroid progenitors and delays the terminal differentiation of
erythrocytes[22]. In our hands, dexamethasone did not prevent
the HMBA-induced initial upregulation of PrP
C in MEL cells,
suggesting that it precedes the effect of dexamethasone, which is
known to suppress the HMBA-mediated commitment to terminal
cell division at a relatively late step in this process[23]. However,
dexamethasone prevented the increase of PrP
C protein levels in
confluent MEL cells after 120 h of culture, demonstrating that the
activation of the glucocorticoid receptor can interfere with the
transcriptional activation of the Prnp gene mediated by cell-cycle
arrest. The mechanism of dexamethasone’s action on the
prevention PrP
C protein upregulation in confluent MEL cells is
unknown at present. Dexamethasone has been shown to induce
cell-cycle arrest in number of various cell lines[24], but not in
MEL cells, in which it increases cell viability[25], both in induced
and uninduced culture. In summary, our results demonstrate that
the regulation of PrP
C levels in differentiating MEL cells
resembles, at least in part, its regulation in maturing mouse
erythroid precursors in vivo. To learn more about the importance
of PrP
C in the process of MEL cells’ differentiation, we created cell
lines using RNAi to stably inhibit expression of the protein. RNAi
Figure 4. Downregulation of PrP
C expression by RNAi in MEL cells after selection with puromycin. (A) Both methods of retroviral vector
delivery led to ,90% silencing of Prnp mRNA in both lines expressing anti-Prnp shRNAmir (LP1 and LP2) when compared with the MEL line
expressing nonsilencing shRNAmir (LN), as depicted by qRT-PCR. (B) Confirmation of PrP
C downregulation in LP1- and LP2-transduced cells at the
protein level by western blot. PrP
C was detected by mAb AH6. No silencing was observed in LP5 cell line. Actin was used as a loading control.
doi:10.1371/journal.pone.0024599.g004
Figure 5. Expression of PrP
C is stably repressed during the differentiation of MEL cells. (A) Level of PrP mRNA measured with qRT-PCR in
cell lines stably expressing anti-Prnp shRNAmir (LP1 and LP2) is downregulated in comparison with control (LN) during the course of cell
differentiation (2 experiments, mean 6 SD). (B) The effect of silencing on the level of PrP
C on cell membrane estimated by quantitative flow
cytometry (four experiments, mean 6 SD. (C) Confirmation of stable PrP
C silencing on the protein level by western blot. PrP
C was detected by mAb
mix AH6, AG4 and 6H4. Actin was used as a loading control.
doi:10.1371/journal.pone.0024599.g005
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employed efficiently to inhibit PrP
C expression in vitro and in
vivo[26,27]. The main objective for using RNAi to suppress PrP
C
was to study its therapeutic potential in preventing propagation of
infectious prions. To the best of our knowledge, our model is the
first murine cell line of non-neuronal origin with stably silenced
PrP
C expression. Inhibition of the protein’s expression at both the
mRNA and protein levels was efficiently maintained during the
differentiation of MEL cells, although it varied between 75 and
95% in individual time points. Despite the silencing, the induction
of differentiation led to a detectable increase of PrP
C signal on
blots after 24 h, suggesting that the regulation of the protein’s
expression in LP1- and LP2-transduced cell lines follows similar
pattern as in unmodified MEL cells, although at a suppressed
level. Growth curve and viability of LP1-, LP2- and control LN-
transduced cell lines after the induction of differentiation was
similar, although the LP2-transduced cell line exhibited a higher
proliferation capacity. Since the LP1-transduced cell line did not
differ from control LN-transduced cell line, we could not assign the
LP2-transduced cell line’s divergence solely to PrP
C silencing. All
cell lines observed here demonstrated similar dynamics and level
of hemoglobinization and regulation of the transferrin receptor on
their cell membranes. This finding suggested that silencing of PrP
C
in MEL cells does not lead to gross perturbation of iron
homeostasis, although the involvement of PrP
C in iron-cell uptake
was described recently[28,29]. Similarly, the level of the proto-
oncogene c-myb, expression of which is characteristic of the
proliferative state and has been demonstrated to block MEL cells’
differentiation[30,31], decreased upon induction similarly in all
created cell lines and remained low during the entire course of the
experiment. Monitoring of selected erythroid markers (AHSP,
Hba and GATA-1) on the transcriptional level also did not reveal
significant differences among LP1-transduced, LP2-transduced
and LN-transduced cell lines, confirmingthat PrP
C silencing does
not appear disturb the differentiation of MEL cells. In many cell
cultures, the enhanced expression of PrP
C was proposed to
facilitate cytoprotective effects[32]. However, overexpression of
exogenously delivered PrP
C in MEL cells did not protect the cells
against apoptosis initiated by serum withdrawal[33]. We also
found that silencing of PrP
C did not seem to sensitize cells to
apoptosis during differentiation, as demonstrated by a Trypan
Blue exclusion assay and by monitoring of Bax expression by
qRT-PCR. This result is concurrent with Christensen and Harris,
who reevaluated former assays reporting a protective activity of
PrP
C and suggested that the presence of PrP
C has only a modest
effect in cytoprotection in vitro[34].
Figure 6. Differentiating MEL cells display similar characteristics irrespective to the level of PrP
C expression. (A) Growth curves of LP1,
LP2 and control LN lines during erythroid differentiation induced by HMBA. (B) Cell viability based on a Trypan Blue exclusion assay. (C)
Concentration of total hemoglobin in the cells per 100 mg/mL of total cell proteins. (D) Number of CD71 (transferrin receptor) molecules per cell,
analyzed by quantitative flow cytometry, based on assumption that one anti- CD71-PE mAb binds one molecule of transferrin receptor.
doi:10.1371/journal.pone.0024599.g006
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PrP
C seems dispensable for the erythroid differentiation of MEL
cells. The pattern of PrP
C regulation on erythroid precursors in vivo
suggeststhat PrP
C mayplaya role inthematuration oferythroblasts
in erythroblastic islands. We can speculate that PrP
C, which was
shown tobindboth lamininandthelamininreceptor[35,36],canbe
involved in cell-cell contacts in an erythroblastic niche, or with a
surrounding extracellular matrix. Downregulation of PrP
C, then,
could play a role in the dissociation of matured reticulocytes from
the erythroblastic niche. Such a role for PrP
C is unlikely to be
detected by the MEL cell model. Another explanation could be that
PrP
C exertsitsfunctiononlyunderstressconditions.Thishypothesis
is consistent with the documented poor recovery of PrP
2/2 mice
from experimental anemia[7]. Finally, it is possible that the effect of
PrP
C silencing was compensated for by an unknown pathway or
that the remaining expression is sufficient to sustain its role.
In conclusion, we created model cell lines with efficiently
silenced expression of PrP
C, which are the first of their kind and
may serve as a valuable tool in subsequent searches for the
function of PrP
C beyond the erythroid differentiation.
Materials and Methods
Flow cytometry of mouse bone marrow and spleen
erythroid precursors
The study was approved by the Committee on the Ethics of Animal
Experiments of the First Faculty of Medicine, Charles University in
Prague (Permit Number: 217/07). Bone marrow (BM) cells were
isolated from the femurs of PrP
+/+ mice (C57BL/66129/SvxCD1
mixed background) by washing with PBS, 1% BSA and 2 mM EDTA,
pH 7.4 (PBS-BE). Spleen and BM cells were passed through a 40-mm
cell strainer (Becton Dickinson, San Diego, CA, USA) to eliminate
stroma and debris. The cells were labeled (30 min, 4uC) withsaturating
concentration of monoclonal antibodies (mAbs): anti-mouse Ter-119
eFluor 450, anti-mouse CD71-FITC (both eBioscience, San Diego,
CA, USA) and AH6 (TSE Resource Center, Roslin, UK), custom
conjugated to PE (Exbio, Vestec, Czech Republic). Labeled cells were
washed and resuspended in PBS-BE, and their fluorescence was
analyzed on a BD FACSCanto II flow cytometer equipped with BD
FACSDiva Software v6.0 (BectonD i c k i n s o n ) .D e a dc e l l sw e r e
excluded from the analysis by 7-aminoactinomycin D (7-AAD)
(Molecular Probes, Eugene, OR, USA) labeling, and the fluorescence
of live cells (10
5) was analyzed. Erythroblast subpopulations were
resolved according Ter119, CD71 and forward-scatter (FSC) signals.
Proerythroblasts (proE) were identified as Ter119
medium CD71
+ cells.
Ter119
high cells were divided using both the CD71 and FSC
parameters into three populations, labeled EryA, EryB and EryC, as
described previously[37], and the binding of the prion mAb AH6 was
quantified using Standard Quantum R-PE MESF beads (Bangs
Laboratories, Fishers, IN, USA)[11,15].
Flow cytometry of cell cultures
Cells were washed with 1% BSA-PBS, pH 7.4 (PBS-B) and
labeled for 20 min at RT with saturating concentrations of the
Figure7.Transcriptionallevelsofselected erythroid markers indifferentiatingMELcells indicatea similarpattern,irrespectivetoPrP
silencing. (A) Expression of Eraf (a-hemoglobin stabilizing protein) and Hba (Hemoglobin a) in LP1- and LP2-transduced cells was compared with the
level in the control LN-transduced cell line on individual days, as measured by qRT-PCR (n=4, mean 6 SD). (B) Representative pattern of Eraf and Hba
expression during differentiation. The level of expression in individual days was normalized to the level in the LN-transduced cell line in day 0.
doi:10.1371/journal.pone.0024599.g007
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washed cells were resuspended in PBS-B and analyzed using a flow
cytometer to standardize the fluorescence readings and to allow for
the quantification of PrP
C and CD71 expression Standard
Quantum R-PE MESF beads were run as a separate sample.
Viable cells were identified as a 7-AAD-negative population.
Cell cultures
The MEL cell line (clone 707, ECACC, Salisbury, UK) and
packaging cell line HEK293 GP2 (Clontech, Mountain View, CA
USA) were maintained in DMEM growth medium containing
high glucose (4.5 g/L), L- glutamine, sodium pyruvate, 10% fetal
bovine serum and puromycin/streptamycin (all reagents from
PAA, Pasching, Austria). Cells were cultured at 37uCi na
humidified atmosphere containing 5% CO2. For all experiments,
MEL cells between the second and fourth passages were seeded at
a density of 10
5 cells/mL 24 h before induction of differentiation
by 5 mM HMBA (final concentration). In some instances, 4 mM
dexamethasone (Sigma-Aldrich, Prague, Czech Republic) was
used to block the commitment of MEL cells. The cells were
incubated with either HMBA, HMBA and dexamethasone or
dexamethasone alone for 24 h, and then the medium was
changed, and the cells were grown in the presence of either
HMBA, dexamethasone, HMBA and dexamethasone, or in
medium only.
Cloning
For the silencing of cellular prion expression, we used
shRNAmir sequences HP_285770 (LP1) and HP_288208 (LP2),
which are available in the RNAi codex database (http://cancan.
cshl.edu/cgi-bin/Codex/Codex.cgi). The shRNAs, together with
the control nonsilencing shRNAmir (LN), were ordered in the
pSM2 retro vectors V2MM_66187, V2MM_63696 and RHS1707
(Open Biosystems, Huntsville, AL, USA)[38]. The third anti- Prnp
mRNA sequence (LP5), adopted from Pfeifer et al., was purchased
as an oligonucleotide[27]. All sequences were cloned into the LMP
retrovector MSCV/LTRmiR30-PIG (Open Biosystems). Con-
structs created in this study were verified by sequencing.
RNAi of Prnp expression
Packaging HEK293 GP2 cells were seeded at a density of
approximately 1.5610
5 cells/well (24-well plate). After 24 h, the
cells were transfected with a mixture of the VSV-G plasmid,
coding the envelope protein of the vesicular stomatitis virus
(Clontech), and the appropriate LMP retrovector (LN, LP1, LP2
or LP5). Plasmids were delivered in a ratio of 9:1 with the Arrest-in
transfection agent (Open Biosystems). Three days after transfec-
tion, media containing retroviral particles were centrifuged (400 g,
4uC) to pellet eventual cell contaminants, and the infectious
supernatant, containing 4 mg/mL Polybrene (Sigma-Aldrich), was
added to MEL cells in a 1:1 ratio. Subsequently, transduced MEL
cells were spun down at 450 g for 90 min at RT (a method known
as spinfection). In a second approach, the MEL cells were infected
by co-cultivation with a packaging cell line. In this method,
medium in HEK293 GP2 cells was aspirated 24 h postinfection,
and 2610
4 MEL cells/well were added inside the 0.4-mm-pore
translucent polyphthalate insert (Becton Dickinson) in a 0.7 mL
total volume of fresh media containing 4 mg/mL Polybrene. After
48 (co-cultivation) or after 72 (spinfection) hours of incubation, the
cells were diluted with fresh medium, and selection started the next
day through the addition of puromycin (Sigma) at a final
concentration of 0.5 mg/mL. The percentage of cells with an
integrated retrovector genome was monitored by FACS utilizing
eGFP positivity. Cell lines prepared by both methods were mixed
after three weeks after reaching .95% eGFP positivity and were
frozen in aliquots.
Western blot and densitometry
Cells were washed in PBS and lysed with 1% TX-100, 0.5%
sodium deoxycholate and 0.1% SDS in 150 mM NaCl, 2 mM
MgCl2 and 50 mM Tris, pH 8.0, supplemented with 12 units/mL
benzonase (Sigma) and the EDTA-free protease inhibitor
Complete (Roche Diagnostics, Basel, Switzerland). Protein
concentration was measured by BCA assay (Thermo Fisher
Scientific, Rockford, IL, USA), and 20 mg proteins/lane were
loaded for SDS-PAGE analysis. Separated proteins were blotted to
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and
PrP
C detected with a mix of the mAbs AH6, AG4 (both 1 mg/mL,
TSE resource center) and 6H4 (0.05 mg/mL, Prionics AG, Zurich,
Switzerland). The anti-actin polyclonal Ab I-19 (Santa Cruz,
Santa Cruz, CA, USA) (0.5 mg/mL) was used as a loading control.
Secondary antibodies were goat anti mouse IgG F(ab)2 alkaline
phosphatase (Biosource) and goat anti rabbit IgG F(ab)2 alkaline
phosphatase (Caltag, Buckhingham, UK), both at a dilution of 1:
4000. BCIP/NBT (Caltag) was used as a chromogen. The density
of bands on blots was quantified using MiniLumi densitometer
software (DNR Bio-Imaging Systems Ltd., Israel).
Reverse transcription and quantitative PCR
RNA was isolated using the RNA Blue solution according to the
manufacturer’s manual (Top-Bio, Prague, Czech Republic).
Contaminating genomic DNA was degraded by treatment with
TURBO DNase (Ambion, Austin, TX, USA). RNA integrity was
evaluated by electrophoresis, and 0.5 mg RNA was reverse-
transcribed with the RevertAid first-strand cDNA synthesis kit
(Fermentas, Burlington, ON, Canada) according to the manufac-
turer’s manual. Complementary DNA was tenfold diluted, and
2 mL were used for qRT-PCR performed in an ABI 7300 PCR
System using TaqMan primers, probes and the Universal PCR
Master Mix (Applied Biosystems, Carlsbad, CA, USA). We
monitored the expression of the following genes: glyceraldehyde-
3-phosphate dehydrogenase (Gapdh), the prion protein (Prnp), the
hemoglobin alpha adult chain 1 (Hba-a1), the myeloblastosis
oncogene (Myb), the a-hemoglobin stabilizing protein (Eraf), the
GATA-binding protein 1 (GATA-1), 29-59 oligoadenylate synthe-
tase 1A (Oas1a), ribonuclease L (Rnase1), the eukaryotic translation
initiation factor 2-alpha kinase 2 (Eif2ak2) and the BCL2-
associated X protein (Bax). Relative expression levels were
calculated using the 2
-DDCT method[39] and normalized to the
reference Gapdh gene. Expression quantities were normalized as
described in results.
Spectrophotometric determination of hemoglobin
content
The hemoglobin concentration in MEL cell lysates was
measured with the TMB assay as described previously, with
adjustments for 96-well plates[40]. The cell lysates were diluted to
contain 100 mg of protein per mL, and their absorbance at
660 nm was measured using a VICTOR
2 D fluorometer
(PerkinElmer, Waltham, Massachusetts, USA). The amount of
hemoglobin was subtracted from the calibration curve composed
of serial dilutions of purified hemoglobin (Sigma).
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